Agendia, Inc. has entered into a Settlement Agreement with the U.S. Department of Justice (DOJ) acting on behalf of the Office of Inspector General of the Department of Health and Human Services (OIG-HHS) to resolve a civil complaint filed in the U.S. District Court for the Western District of Kentucky in March of 2015. This civil action was filed by a private party acting on behalf of the government under seal pursuant to the False Claims Act, 31 U.S.C. § 3730(b), which alleged that the Company circumvented Medicare’s 14-Day Rule causing false claims to be submitted to Medicare from July 1, 2010 to June 9, 2017.

Importantly, the Settlement Agreement expressly acknowledges that (1) Agendia denies any and all wrongdoing and (2) does not constitute an admission of liability by the Company. Agendia chose to resolve the matter in this way because the Company felt that this course of action offered the best use of our Company’s energy and resources to move forward and reach our goal of being the leader in precision oncology for breast cancer patients. We remain focused on the business at hand: helping breast cancer patients and their physicians make critical and timely treatment decisions for the best outcomes.

Agendia’s mission continues to be to provide clarity to women with breast cancer on current and future treatments. We do this with a sense of urgency because every day counts when a woman is diagnosed with breast cancer.

Media Contacts:

Dina Scaglione
Director, Marketing
Tel: 949.910.9401

Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326